JP4799116B2

JP4799116B2 - 検体分析装置、検体分析方法及びコンピュータプログラム

検体分析装置、検体分析方法及びコンピュータプログラム Download PDF

Info

Publication number: JP4799116B2
Authority: JP; Japan
Prior art keywords: sample; abnormality; time; coagulation; reaction
Prior art date: 2005-10-11
Legal status : Expired - Fee Related

Application number

JP2005295906A

Other languages

English (en)

Japanese (ja)

Other versions

JP2007107889A (ja

JP2007107889A5 (enExample

Inventor

満代伊藤

直彦松尾

Current Assignee

Sysmex Corp

Original Assignee

Sysmex Corp

Priority date

2005-10-11

Filing date

2005-10-11

Publication date

2011-10-26

2005-10-11 Application filed by Sysmex Corp filed Critical Sysmex Corp

2005-10-11 Priority to JP2005295906A priority Critical patent/JP4799116B2/ja

2007-04-26 Publication of JP2007107889A publication Critical patent/JP2007107889A/ja

2008-11-27 Publication of JP2007107889A5 publication Critical patent/JP2007107889A5/ja

2011-10-26 Application granted granted Critical

2011-10-26 Publication of JP4799116B2 publication Critical patent/JP4799116B2/ja

2025-10-11 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

238000004590 computer program Methods 0.000 title claims description 20
238000012284 sample analysis method Methods 0.000 title claims description 5
238000005259 measurement Methods 0.000 claims description 146
238000006243 chemical reaction Methods 0.000 claims description 89
230000005856 abnormality Effects 0.000 claims description 84
238000004458 analytical method Methods 0.000 claims description 57
230000008859 change Effects 0.000 claims description 51
238000000034 method Methods 0.000 claims description 40
239000003153 chemical reaction reagent Substances 0.000 claims description 32
230000003287 optical effect Effects 0.000 claims description 30
230000008569 process Effects 0.000 claims description 29
230000002159 abnormal effect Effects 0.000 claims description 22
108010049003 Fibrinogen Proteins 0.000 claims description 8
102000008946 Fibrinogen Human genes 0.000 claims description 8
229940012952 fibrinogen Drugs 0.000 claims description 8
238000004364 calculation method Methods 0.000 claims description 6
239000008280 blood Substances 0.000 claims description 5
210000004369 blood Anatomy 0.000 claims description 5
230000023555 blood coagulation Effects 0.000 claims description 5
238000012544 monitoring process Methods 0.000 claims description 5
230000015271 coagulation Effects 0.000 description 115
238000005345 coagulation Methods 0.000 description 115
238000007711 solidification Methods 0.000 description 29
230000008023 solidification Effects 0.000 description 29
230000007246 mechanism Effects 0.000 description 15
206010053567 Coagulopathies Diseases 0.000 description 14
230000035602 clotting Effects 0.000 description 14
238000004891 communication Methods 0.000 description 11
238000003780 insertion Methods 0.000 description 10
230000037431 insertion Effects 0.000 description 10
230000007423 decrease Effects 0.000 description 9
230000032258 transport Effects 0.000 description 9
238000012545 processing Methods 0.000 description 8
230000007723 transport mechanism Effects 0.000 description 8
238000012546 transfer Methods 0.000 description 6
238000010586 diagram Methods 0.000 description 5
238000012360 testing method Methods 0.000 description 5
102000009123 Fibrin Human genes 0.000 description 3
108010073385 Fibrin Proteins 0.000 description 3
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 3
238000002835 absorbance Methods 0.000 description 3
230000000694 effects Effects 0.000 description 3
229950003499 fibrin Drugs 0.000 description 3
108010094028 Prothrombin Proteins 0.000 description 2
102100027378 Prothrombin Human genes 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
239000004973 liquid crystal related substance Substances 0.000 description 2
229940039716 prothrombin Drugs 0.000 description 2
PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
108010000499 Thromboplastin Proteins 0.000 description 1
102000002262 Thromboplastin Human genes 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
210000001175 cerebrospinal fluid Anatomy 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000002250 progressing effect Effects 0.000 description 1
238000011002 quantification Methods 0.000 description 1
238000013102 re-test Methods 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000000126 substance Substances 0.000 description 1
230000002123 temporal effect Effects 0.000 description 1
210000002700 urine Anatomy 0.000 description 1